SupplySide West: Inclusivity in clinical trialsSupplySide West: Inclusivity in clinical trials
Clinical trials are only as good as the quality of the study cohort. Recruiting the right subjects for your trial yields the best data. Price: $50
Already purchased?
At a Glance
- Clinical trials are necessary, but expensive.
- Recruiting the right subjects yields the best data.
- That in turn yields the best return on investment.
As the consumer demand for clinical substantiation increases, the industry must respond accordingly. Not only must products and ingredients do what they claim, they must also reflect the population for which they are formulated. This session focuses on how clinical trials can be designed to show measurable results. The session also focuses on the area of inclusivity in clinical trial design and how improving that aspect can yield more actionable data. The session includes presentations by David Foreman, The Herbal Pharmacist and Susan Hewlings, vice president of research affairs for Radicle Science. Those presentations are followed by a panel discussion including moderator Duffy Hayes of Informa, Erin Lewis, scientific director of KGK Science, Barry Skillington, chief commercial officer of Altantia Clinical Trials and Douglas Kalman, clinical associate professor at Nova Southeastern University.
Timeline
0:00 to 5:15. Intro and questions to audience.
5:15 to 12:30. David Foreman presentation.
12:30 to 26:35. Susan Hewlings presentation.
26.35 to 31:15. Start of panel discussion, focusing first on what are the key elements in setting up an inclusive trial. Issues in recruitment, including making the clinic environment as non-threatening as possible, are addressed.
31:15 to 33:30. Discussion of importance of keeping the target market for a product in mind when recruiting subjects for trials.
33:30 to 37:30. Screening protocols for recruiting subjects.
38:00 to 60:00. Questions from audience.
Price: $50
Read more about:
Premium contentAbout the Author
You May Also Like